| J R Vyas, managing director of Dishman Pharma, said, "There is huge potential in biotech and nanotechnolgy research and it's the right area to venture into. We have asked some of the merchant bankers to identify the potential biotech and nanotechnology CRO companies for possible acquisition in Europe and the US." |
| He said the acquisition would be done through their wholly-owned subsidiary Carbogen Amcis AG. Though the company has not taken any concrete steps towards acquisition, it has mobilised resources to identify the companies. |
| Vyas is confident that the acquisition would be completed by 2008-mid. |
| Switzerland-based Carbogen Amcis AG provides process research services with a core competency in active pharmaceutical ingredients (APIs) along with full-scale manufacturing service. |
| According to the company, the new acquisition will put Carbogen Amcis on the growth path. |
| The company believes that Carbogen Amcis, with a pool of 171 PhD research, will be in a much more better position to utilise their expertise to develop the biotech and nanotech CROs under it. |
| The company is not looking for large-sized CROs but knowledge-based acquisition, particularly those companies that possess intellectual property rights (IPR) for their products. |
| "We would like to acquire a CRO company that falls between the $ 5 million and $ 20 million range," added Vyas. |
| The company is also planning to move out some of its Swiss subsidiary's large-sized contract manufacturing project work to its Ahmedabad facility. |
| The Swiss subsidiary's largest reactor can process 300 litres of drugs, while Dishman's Indian operation's smallest reactor is of this size. |
| The company informed that four clients of its Swiss subsidiary will shortly visit Ahmedabad to examine the company's USFDA-approved facility for sourcing out the contract manufacturing project work to India. |
| Dishman's existing businesses are expected to post revenues of Rs 350 crore in FY 2006-07. |
Top Section
Explore Business Standard